Royalty Report: Drugs, Nutraceutical, Food – Collection: 4735


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 7


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7

Primary Industries

  • Drugs
  • Nutraceutical
  • Food
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4735

License Grant
The Licensor was assigned the License agreement related to dietary supplements and drugs, by the original Licensor in a Stock Purchase Agreement.
License Property
Dietary supplements including glucan and fulvic acid and herbal enhanced analgesic formulations.
Field of Use
Licensee is a biotechnology company engaged in the research and development, marketing and sale of lifestyle, dietary supplements and drugs.

IPSCIO Record ID: 3311

License Grant
In the six months ended June 30, 2014, the Licensee incurred $88 thousand of expense based on the Research and Royalty Agreement with the Licensor, under which the Licensee is obligated to pay a royalty on all Anatabloc® sales.
License Property
Anatabine is used as a dietary supplement and as a drug. The dietary supplements are known as Anatabloc.

IPSCIO Record ID: 27269

License Grant
The Company acquired from shareholder and former President of the Company of Israel, exclusive rights and interests to a thirteen step process which utilizes virtually the whole of the nutrients found in plants to manufacture herbal dietary supplements.

IPSCIO Record ID: 422

License Grant
The University grants to Company a world-wide exclusive license under Patent Rights and Technical Information, with the right to grant sublicensees, to make, have made, use, sell, offer for sale, export, import and otherwise deal with Licensed Product,  for application thereof to dietary supplements and pharmaceutical products, including over-the-counter products, prescription drugs, OTC drugs and generic drugs.
License Property
Product shall mean (i) any dietary supplement (as defined in the 1994 Dietary Supplement and Health Education Act) (referred to herein as a Supplement); (ii) any drug which can be purchased by the general public without a prescription (referred to herein as OTC Drug); and (iii) any prescription drug (whether existing at the time of this Agreement or yet to be discovered).

Patent Application 09/037,096 and PCT Application PCT/US99/04508 related thereto, for application thereof to dietary supplements and pharmaceutical products, including over-the-counter products, prescription drugs, OTC drugs and generic drugs.

IPSCIO Record ID: 1422

License Grant
Pursuant to the licensing Agreement the Licensee obtained the exclusive, worldwide, perpetual License to X-Fat, a fat-fighting dietary supplement.
License Property
The Licensor is the former owner of the X-Fat Patent.
Field of Use
X-Fat® is a patented dietary supplement that uses Kytabsorbe®, a liquid form of the natural fat fighter, chitosan. Chitosan has been studied extensively by the scientific community and has been shown to bind to a variety of dietary fats.

IPSCIO Record ID: 5244

License Grant
The Company’ newly acquired subsidiary, exclusively licensed patents related to amino acid based dietary supplements to enhance the level of endogenous nitric oxide in the vascular system from the University.

IPSCIO Record ID: 3225

License Grant
The parties entered an agreement for the sales of Anatabloc®.
License Property
The Research Institute is devoted to understanding causes of and finding cures for neuropsychiatric and neurodegenerative disorders and addictions.

Anatabloc®,is a neutraceutical dietary supplement for anti-inflammatory support introduced in August, 2011.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.